|
Neuren completes enrolment in Phelan-McDermid Phase 2 trial
|
30 June 2023 at 10:00am
|
|
Neuren opens first site in US for Prader-Willi Phase 2 trial
|
28 June 2023 at 10:20am
|
|
Change of Director's Interest Notice
|
14 June 2023 at 7:10pm
|
|
Neuren receives US$40m milestone payment
|
7 June 2023 at 3:45pm
|
|
Neuren presenting at Jefferies Global Healthcare Conference
|
5 June 2023 at 5:00pm
|
|
Results of Meeting
|
30 May 2023 at 5:00pm
|
|
AGM Chair Address & CEO Presentation
|
30 May 2023 at 2:10pm
|
|
Notice of Annual General Meeting/Proxy Form
|
28 April 2023 at 9:59am
|
|
Virtual AGM online guide
|
28 April 2023 at 9:50am
|
|
Q1 2023 quarterly activity and cash flow report
|
28 April 2023 at 9:50am
|
|
Appendix 4G
|
27 April 2023 at 9:50am
|
|
2022 Annual Report to shareholders
|
27 April 2023 at 9:50am
|
|
DAYBUE (trofinetide) launched in US - Neuren earns US$40m
|
18 April 2023 at 10:20am
|
|
Application for quotation of securities - NEU
|
27 March 2023 at 1:55pm
|
|
Investor Presentation, 14 March 2023
|
14 March 2023 at 9:00am
|
|
Notification of investor webinar
|
13 March 2023 at 2:59pm
|
|
FDA approves Daybue - the first treatment for Rett syndrome
|
13 March 2023 at 9:35am
|
|
Initial Director's Interest Notice
|
2 March 2023 at 10:00am
|
|
Neuren appoints Joe Basile to board of directors
|
2 March 2023 at 9:55am
|
|
Investor presentation, 1 March 2023
|
1 March 2023 at 1:45pm
|
|
Investor Presentation, 24 February 2023
|
24 February 2023 at 3:59pm
|
|
Neuren reports 2022 full-year results
|
24 February 2023 at 10:05am
|
|
Appendix 4E and 2022 full year accounts
|
24 February 2023 at 9:55am
|
|
Application for quotation of securities - NEU
|
21 February 2023 at 4:45pm
|
|
Q4 2022 quarterly activity and cash flow report
|
31 January 2023 at 10:10am
|
|
Prader-Willi syndrome IND for NNZ-2591 approved by FDA
|
23 January 2023 at 9:55am
|
|
Neuren submits IND & first patients complete Phase 2 trials
|
23 December 2022 at 10:10am
|
|
Becoming a substantial holder
|
7 December 2022 at 10:45am
|
|
Ceasing to be a substantial holder
|
2 December 2022 at 8:00am
|
|
Change in substantial holding
|
23 November 2022 at 12:35pm
|
|
Jefferies London Healthcare Conference 2022 presentation
|
18 November 2022 at 9:25am
|
|
Q3 2022 quarterly activity and cash flow report
|
27 October 2022 at 10:00am
|
|
Neuren receives US$10 million milestone payment
|
20 October 2022 at 9:55am
|
|
Investor presentation, 14 September 2022
|
14 September 2022 at 1:20pm
|
|
Rett Syndrome NDA accepted for Priority Review by FDA
|
13 September 2022 at 9:35am
|
|
S&P DJI Announces September 2022 Quarterly Rebalance
|
2 September 2022 at 5:30pm
|
|
Half-year shareholder update
|
24 August 2022 at 9:55am
|
|
Half Yearly Report and Accounts
|
24 August 2022 at 9:40am
|
|
Investor presentation, 8 August 2022
|
8 August 2022 at 9:50am
|
|
Neuren commences Phase 2 trials of NNZ-2591 in PMS and PTHS
|
8 August 2022 at 9:35am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 July 2022 at 10:10am
|
|
Acadia submits Rett Syndrome New Drug Application to the FDA
|
19 July 2022 at 10:15am
|
|
Neuren commences Phase 2 trial of NNZ-2591 in Angelman
|
12 July 2022 at 10:05am
|
|
Notification regarding unquoted securities - NEU
|
8 July 2022 at 12:45pm
|
|
Neuren appoints Chief Medical Officer in United States
|
8 July 2022 at 12:25pm
|
|
Results of Meeting
|
30 May 2022 at 5:00pm
|
|
AGM Chairman's Address & CEO Presentation
|
30 May 2022 at 2:45pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
29 April 2022 at 1:20pm
|
|
Virtual AGM online guide
|
28 April 2022 at 10:15am
|
|
Notice of Annual General Meeting/Proxy Form
|
28 April 2022 at 10:05am
|
Neuren Pharmaceuticals